Fig. 2From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trialPFS in relation to Haplo1/Haplo1 (top panels) or Haplo1/Haplo1 plus Haplo2/Haplo2 (bottom panels) genotypes in patients treated with CT + B (a, c) or CT (b, d).Back to article page